Novel Agent First to Slow Disability in nrSPMS - Medscape
WEB23 hours ago · September 20, 2024. 0. 0. COPENHAGEN, Denmark — A new investigational drug has become the first agent to slow disability in patients with nonrelapsing secondary progressive multiple sclerosis ...
Key biomarkers identified for predicting disability ...
WEB1 day ago · A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple sclerosis (MS). The breakthrough research has the potential to transform ...
The Promising Results of Tolebrutinib for Secondary ...
WEB1 day ago · "We have finally identified a therapy that slows the insidious progression of secondary progressive [multiple sclerosis], giving hope to slow this form of the disease." Tolebrutinib (Sanofi), a Bruton’s tyrosine kinase (BTK) inhibitor that targets B cells and microglia, has the potential to modulate both peripheral and central pathologic ...
National MS Society updates Pathways to Cures Roadmap
WEBSep 11, 2024 · by Steve Bryson, PhD September 11, 2024. The National Multiple Sclerosis Society (NMSS) has updated its Pathways to Cures Roadmap to account for recent scientific advances in the search for a cure ...
Multiple Sclerosis News Today | Symptoms, Diagnosis, Treatments
WEB5 days ago · Get the latest multiple sclerosis news, patient views, and caregiver perspectives from one of the largest MS communities online.
A Cure for Multiple Sclerosis? Scientists Say Within Our ...
WEBJun 12, 2024 · A generation ago, most people with multiple sclerosis could expect to rely on walkers and wheelchairs or be limited to their bed within 15 years of diagnosis. Today, UC San Francisco’s discoveries are keeping millions with MS healthier for longer – many disability-free. Now, the university is paving the way for an MS cure in our lifetimes.
'Major moment in MS research' as new Octopus trial starts - BBC
WEBApr 4, 2023 · The Octopus trial - so-called because it is a multi-arm, multi-stage trial - is being run by Prof Jeremy Chataway, from the National Hospital for Neurology and Neurosurgery UCLH in London, with £ ...
CAR-T therapy for multiple sclerosis enters US trials for ...
WEBFeb 22, 2024 · Multiple sclerosis (MS) is an autoimmune disease, driven by misguided T and B cells that attack nerve cells. ... An essential round-up of science news, opinion and analysis, delivered to your ...
FDA Approves First Biosimilar to Treat Multiple Sclerosis
WEBAugust 24, 2023. Spanish. The U.S. Food and Drug Administration today approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with ...
Early treatment could slow the onset of multiple sclerosis ...
WEBApr 19, 2023 · By Kaitlin Sullivan. Starting treatment for multiple sclerosis early — before symptoms even begin — could possibly delay the onset of the condition, new research finds. Preliminary results of ...
Skip to content